ELEVATE Study: Design
Hope S. Rugo, MD, FASCO, discusses how the phase 3 ELEVATE study evaluates the combination of elacestrant with abemaciclib in patients with ER+/HER2– advanced or MBC who have progressed on prior endocrine therapy.
Related Articles
Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL
Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study | JCO Global Oncology
PURPOSETrimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM),…
Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL
Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.
Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Optimizing Treatment Sequences Remains Key in CLL/SLL
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.
US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL
Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.
OCE PULSE: January FDA Oncology Events, Recent Approvals and Publications
Click to share this newsletter with your colleagues! OCE PULSE offers a summary of FDA Oncology Center of Excellence (OCE) upcoming public events, educational opportunities,…
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in…
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in…